Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 150 of 6351
-
Can tighter blood pressure control save hearts in diabetes? massive trial aims to find out
Disease control CompletedHigh blood pressure (BP) is a major public health concern, especially in low and middle income countries. High BP is a highly prevalent condition, and it is usually associated with diabetes mellitus. Both high BP and diabetes are risk factors for major cardiovascular events inclu…
Sponsor: Hospital Israelita Albert Einstein • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug shows promise in preventing SMA in newborns
Disease control OngoingA global study of oral risdiplam in pre-symptomatic participants with spinal muscular atrophy (SMA).
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Immunotherapy combo shows promise against Hard-to-Treat colorectal cancer
Disease control OngoingThe main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Micro…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Massive brain cancer trial aims to find better treatments
Disease control Recruiting nowGlioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enro…
Phase 2/3 • Sponsor: Global Coalition for Adaptive Research • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Immunotherapy combo takes on Hard-to-Treat prostate cancer
Disease control CompletedThe purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC, are abiraterone-naïve, …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could an immunotherapy booster improve lung cancer treatment?
Disease control OngoingThis phase III trial studies how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in differen…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug aims to cut sickle cell pain crises in half
Disease control OngoingThe purpose of this study is to compare the efficacy and safety of 2 doses of crizanlizumab (5.0 mg/kg and 7.5 mg/kg) versus placebo in adolescent and adult sickle cell disease (SCD) patients with history of vaso-occlusive crisis (VOC) leading to healthcare visit.
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Immunotherapy combo aims to boost bladder cancer surgery outcomes
Disease control OngoingThis is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that perioperative pembrolizumab plus ra…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can a targeted drug boost the fight against an aggressive blood cancer?
Disease control OngoingThe STELLAR trial will assess the effect of acalabrutinib taken in combination with CHOP-R compared to taking CHOP-R alone in patients with newly diagnosed Richter's Syndrome (RS). It will also be a platform to test other new drugs that show potential for treating RS. Chronic lym…
Phase 2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a shot help people with multiple food allergies eat peanuts safely?
Disease control CompletedThis study is a multi-center, randomized, double-blind, placebo-controlled study in participants 1 to less than 56 years of age who are allergic to peanut and at least two other foods (including milk, egg, wheat, cashew, hazelnut, or walnut). While each participant may be allergi…
Phase 3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 26, 2026 16:10 UTC
-
Immunotherapy plus chemo shows promise in advanced uterine cancer trial
Disease control OngoingThis is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplat…
Phase 3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:51 UTC
-
Personalized mRNA vaccine shows promise in fighting melanoma return
Disease control OngoingThe purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new pill keep HER2-Positive breast cancer from coming back?
Disease control OngoingThis is a randomised, double-blind multicenter Phase III study for evaluating the efficacy and safety of pyrotinib in women with early stage high-risk breast cancer after adjuvant trastuzumab. The main purpose of this study is to investigate whether pyrotinib can further reduce t…
Phase 3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Radioactive antibody targets cancer before stem cell transplant in High-Risk leukemia trial
Disease control Recruiting nowThis phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back (recurrent) or isn't …
Phase 1/2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New pill shows promise for regrowing hair in severe alopecia
Disease control CompletedThe reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a gut hormone boost islet transplants and free type 1 diabetes patients from insulin shots?
Disease control Recruiting nowThis clinical study will evaluate the safety and effectiveness of Gastrin treatment with islet transplantation to help patients with difficult to control type 1 diabetes make insulin again and improve blood sugar control. This study involves two investigational (experimental) pr…
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Promising combo therapy aims to beat back childhood blood cancers
Disease control OngoingThis phase III trial studies how well blinatumomab works in combination with chemotherapy in treating patients with newly diagnosed, standard risk B-lymphoblastic leukemia or B-lymphoblastic lymphoma with or without Down syndrome. Monoclonal antibodies, such as blinatumomab, may …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Promising combo may delay drug resistance in lung cancer patients
Disease control OngoingThe reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cel…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo shows promise against deadly thyroid cancer
Disease control OngoingThis study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.
Phase 2 • Sponsor: National Cancer Center Hospital East • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Training the immune system to hunt down leftover liver cancer cells
Prevention OngoingHepatocellular carcinoma (HCC) is the most common primary liver tumor. Surgical resection remains the first choice for early-stage HCC because the result is superior to other treatments and not limited to liver donation. However, liver resection is criticized because the tumor re…
Phase 2 • Sponsor: Chang Gung Memorial Hospital • Aim: Prevention
Last updated Jul 26, 2026 00:00 UTC